CASI Pharmaceuticals Faces Nasdaq Delisting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Feb 25 2026
0mins
Source: seekingalpha
- Delisting Notice: CASI Pharmaceuticals received a determination letter from Nasdaq regarding its delisting due to failure to meet continued listing requirements, with trading expected to be suspended on February 26, 2026, indicating significant compliance challenges for the company.
- No Appeal Planned: The company has decided not to appeal Nasdaq's delisting decision, which may reflect management's resignation regarding its current financial situation and a cautious outlook on future market conditions.
- OTC Market Trading: Following delisting, CASI's shares are expected to be quoted on the OTC market, although continued trading is not guaranteed, potentially impacting investor liquidity and confidence, thereby exacerbating market uncertainty.
- Historical Performance Review: CASI Pharmaceuticals previously received an extension from Nasdaq to meet listing rules but failed to do so, highlighting ongoing financial and operational difficulties that may affect its future financing capabilities and market competitiveness.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
